San Diego, CA, November 1, 2018 – Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the Chimeric ID Panel designed to reduce the time and cost of performing chimerism analysis for bone marrow engraftment monitoring studies. The SNP-based panel is designed for research use with the MassARRAY® system and is accompanied by software which calculates the composition of a post-transplant follow-up specimen in seconds and displays the results in an easy-to-interpret report.
“This panel boosts lab efficiency by replacing cumbersome methods involving capillary electrophoresis and STR analysis” said Peter Dansky, Chief Executive Officer of Agena. “The simplified workflow and automated reporting reduce the burden on specialized staff and allow results to be calculated much faster than traditional methods.”
The announcement was made during the Association for Molecular Pathology annual meeting in San Antonio, TX.
“AMP is the perfect venue for this discussion” said Dr. Darryl Irwin, Senior Director of Scientific Affairs for Agena following an industry workshop highlighting the panel. “Molecular laboratories are being asked to process increasing numbers of samples using a time-consuming method run on a platform with limited utility. This panel simplifies bone marrow engraftment studies that monitor chimerism and gives labs access to other MassARRAY applications such as cancer profiling for liquid biopsies and pharmacogenetics to name a few.”
About Agena Bioscience
Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY® System. The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis, and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research. For more information about Agena, visit www.agenabio.com.